Clinical results of fibroblast activation protein (FAP) specific PET for non-malignant indications: systematic review.

FAP Fibroblast activation protein Fibroblasts PET PET-CT Positron emission tomography

Journal

EJNMMI research
ISSN: 2191-219X
Titre abrégé: EJNMMI Res
Pays: Germany
ID NLM: 101560946

Informations de publication

Date de publication:
19 Feb 2021
Historique:
received: 11 12 2020
accepted: 10 02 2021
entrez: 19 2 2021
pubmed: 20 2 2021
medline: 20 2 2021
Statut: epublish

Résumé

Small molecules targeting fibroblast activation protein (FAP) have emerged as a new group of tracers for positron emission tomography (PET) in 2018. While most of the existing literature has been focussed on the application of FAP-specific PET in various kinds of cancers, some researchers have, both intentionally or unintentionally, used FAP-specific PET in patients with non-cancerous diseases. The purpose of this systematic review is therefore to summarize the available evidence of FAP-specific PET for non-malignant indications. The MEDLINE database was searched for studies presenting the clinical use of FAP-specific PET, the records were screened according to PRISMA guidelines and articles containing patients suffering from non-malignant diseases were included. Sixteen studies with 303 patients were included. FAP-specific PET has been used in cardiac imaging, IgG While publications on FAP-specific PET for non-malignant indications are mostly limited to case reports and incidental findings, the first retrospective and prospective studies present promising results for IgG

Identifiants

pubmed: 33606104
doi: 10.1186/s13550-021-00761-2
pii: 10.1186/s13550-021-00761-2
pmc: PMC7895887
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

18

Références

Eur J Nucl Med Mol Imaging. 2020 Sep 8;:
pubmed: 32901354
Eur J Nucl Med Mol Imaging. 2020 Aug 28;:
pubmed: 32857182
Nuklearmedizin. 2019 Sep;58(5):371-378
pubmed: 31486054
Clin Nucl Med. 2021 Feb 1;46(2):e86-e87
pubmed: 32701818
J Nucl Med. 2020 Aug;61(8):1171-1177
pubmed: 31836685
Eur J Nucl Med Mol Imaging. 2021 Jan;48(1):196-203
pubmed: 32468254
J Nucl Med. 2019 Mar;60(3):386-392
pubmed: 30072500
Clin Nucl Med. 2020 Apr;45(4):310-311
pubmed: 31977474
Eur J Nucl Med Mol Imaging. 2020 Aug;47(9):2078-2079
pubmed: 32385646
J Clin Oncol. 2019 Jun 20;37(18):1558-1565
pubmed: 31067138
J Nucl Med. 2020 Apr;61(4):620
pubmed: 31420500
Ann Rheum Dis. 2020 Nov;79(11):1485-1491
pubmed: 32719042
AJR Am J Roentgenol. 2021 Feb;216(2):307-308
pubmed: 32755204
J Nucl Cardiol. 2020 Aug 16;:
pubmed: 32803676
JACC Cardiovasc Imaging. 2015 Dec;8(12):1466-1468
pubmed: 26699115
Circ Cardiovasc Imaging. 2020 Sep;13(9):e011603
pubmed: 32912028
J Nucl Med. 2018 Sep;59(9):1415-1422
pubmed: 29626119
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Analyst. 2019 Aug 5;144(16):4935-4942
pubmed: 31313760
Clin Nucl Med. 2020 Aug;45(8):632-635
pubmed: 32453079
J Mol Cell Cardiol. 2015 Oct;87:194-203
pubmed: 26319660
Eur Heart J. 2020 Mar 1;41(9):1060
pubmed: 31630152
Molecules. 2020 Aug 12;25(16):
pubmed: 32806623
J Nucl Med. 2018 Sep;59(9):1423-1429
pubmed: 29626120
Radiother Oncol. 2020 Sep;150:159-163
pubmed: 32598977
Clin Nucl Med. 2020 Nov;45(11):913-915
pubmed: 32910045
Clin Nucl Med. 2020 Jul;45(7):566-567
pubmed: 32371618
J Mater Chem B. 2018 Mar 14;6(10):1449-1451
pubmed: 32254208
Eur J Nucl Med Mol Imaging. 2020 Jul;47(8):1820-1832
pubmed: 32222810
Clin Cancer Res. 2020 Sep 15;26(18):4882-4891
pubmed: 32636317
JACC Cardiovasc Imaging. 2015 Dec;8(12):1417-1426
pubmed: 26577262
Clin Nucl Med. 2020 Oct;45(10):784-786
pubmed: 32796242
Methods. 2020 May 7;:
pubmed: 32389748
Breast J. 2017 Jul;23(4):401-409
pubmed: 28117517
Eur J Nucl Med Mol Imaging. 2020 Jul;47(8):2040-2041
pubmed: 31814067
Eur J Nucl Med Mol Imaging. 2019 Nov;46(12):2569-2580
pubmed: 31388723
Clin Nucl Med. 2020 Jun;45(6):468-470
pubmed: 32149789
Eur J Radiol. 2020 Jun;127:109021
pubmed: 32344293
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3):656-65
pubmed: 20159360
Circ Cardiovasc Imaging. 2020 Sep;13(9):e010628
pubmed: 32912030
Circ Res. 2016 Jun 10;118(12):1906-17
pubmed: 27140435
Rheumatology (Oxford). 2018 Apr 1;57(4):737-747
pubmed: 29361119
Eur J Nucl Med Mol Imaging. 2020 Aug;47(9):2080-2082
pubmed: 32440890
EJNMMI Radiopharm Chem. 2020 Jul 29;5(1):19
pubmed: 32728930
J Nucl Cardiol. 2020 Sep 25;:
pubmed: 32975729
Data Brief. 2020 May 15;31:105712
pubmed: 32490080
J Nucl Med. 2021 Feb;62(2):201-207
pubmed: 32591493
Cancers (Basel). 2020 Sep 15;12(9):
pubmed: 32942573
Anal Chem. 2019 Aug 6;91(15):10197-10203
pubmed: 31264843
Eur J Nucl Med Mol Imaging. 2020 Jul 10;:
pubmed: 32651662
Clin Nucl Med. 2021 Feb 1;46(2):e78-e79
pubmed: 32804764
Clin Nucl Med. 2020 Oct;45(10):e430-e432
pubmed: 32332301
J Nucl Med. 2021 Feb;62(2):266-271
pubmed: 32513902
Eur J Nucl Med Mol Imaging. 2021 Jan;48(1):73-86
pubmed: 32588089
J Nucl Med. 2019 Dec;60(12):1743-1749
pubmed: 31405922
Clin Nucl Med. 2020 Apr;45(4):312-313
pubmed: 31977476
J Nucl Med. 2020 Sep;61(9):1331-1336
pubmed: 32060216
AJR Am J Roentgenol. 2021 Feb;216(2):305-306
pubmed: 32755205
JACC Cardiovasc Imaging. 2018 Oct;11(10):1541-1543
pubmed: 29454781
J Nucl Med. 2019 Jun;60(6):801-805
pubmed: 30954939
Eur J Nucl Med Mol Imaging. 2019 Nov;46(12):2625-2626
pubmed: 31410541
Eur J Nucl Med Mol Imaging. 2019 Jul;46(8):1754-1755
pubmed: 31119317
Eur J Nucl Med Mol Imaging. 2021 Feb;48(2):647-648
pubmed: 32632460
Eur J Nucl Med Mol Imaging. 2021 Feb;48(2):651-652
pubmed: 32643006
Theranostics. 2020 Apr 27;10(13):5778-5789
pubmed: 32483418

Auteurs

Paul Windisch (P)

Department of Radiation Oncology, Kantonsspital Winterthur, Brauerstrasse 15, 8400, Winterthur, Switzerland. paul.windisch@ksw.ch.

Daniel R Zwahlen (DR)

Department of Radiation Oncology, Kantonsspital Winterthur, Brauerstrasse 15, 8400, Winterthur, Switzerland.

Frederik L Giesel (FL)

Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany.

Eberhard Scholz (E)

Department of Cardiology, Heidelberg University Hospital, Heidelberg, Germany.
Heidelberg Center for Heart Rhythm Disorders (HCR), Heidelberg University Hospital, Heidelberg, Germany.
DZHK (German Centre for Cardiovascular Research), Partner Site Heidelberg/Mannheim, University of Heidelberg, Heidelberg, Germany.

Patrick Lugenbiel (P)

Department of Cardiology, Heidelberg University Hospital, Heidelberg, Germany.
Heidelberg Center for Heart Rhythm Disorders (HCR), Heidelberg University Hospital, Heidelberg, Germany.

Jürgen Debus (J)

Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.
Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.
National Center for Tumor Diseases (NCT), Heidelberg, Germany.
Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Heidelberg Ion-Beam Therapy Center (HIT), Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.
German Cancer Consortium (DKTK), Partner Site, Heidelberg, Germany.

Uwe Haberkorn (U)

Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany.
Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Translational Lung Research Center Heidelberg (TLRC), German Center for Lung Research (DZL), Heidelberg, Germany.

Sebastian Adeberg (S)

Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.
Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.
National Center for Tumor Diseases (NCT), Heidelberg, Germany.
Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Heidelberg Ion-Beam Therapy Center (HIT), Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.
German Cancer Consortium (DKTK), Partner Site, Heidelberg, Germany.

Classifications MeSH